Aravax
PrivateLast Round
Series B
Jan 23, 2024
Total Funding Raised
$48.06M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Aravax is a biotechnology company developing next-generation immunotherapies for food allergies, with a lead product candidate, PVX108, for the treatment of peanut allergy.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Aravax Comparables
Compare Aravax with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Prota Therapeutics | 85% | |
| IgGenix | 84% | |
| Ukko | 83% | |
Aravax Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 23, 2024 | ||||
| Series A | May 29, 2018 | ||||
| Seed | Nov 23, 2015 |
Aravax Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| UniSuper Management | Series B |
| Agati Capital | Series B |
| Victorian Government | Series B |
| Uniseed | Series B |
| Tenmile | Series B |
| Brandon Capital | Series A, Series B |
| Breakthrough Victoria | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 25, 2026
Grew 20% QoQ, from 15 to 18 employees.
- Jun 2, 2025
Preparing for Phase 3 development of therapeutic product.
Aravax Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Aravax's valuation, stock price, and market status.